Table of Contents Author Guidelines Submit a Manuscript
Journal of Parasitology Research
Volume 2011, Article ID 636857, 6 pages
Clinical Study

Mebendazole Compared with Secnidazole in the Treatment of Adult Giardiasis: A Randomised, No-Inferiority, Open Clinical Trial

1Faculty of Medicine “Manuel Fajardo”, 10400 Havana City, Cuba
2Academic Paediatric Hospital “Pedro Borrás”, 10400 Havana City, Cuba
3Carlos J. Finlay Hospital, 11500 Havana City, Cuba
4Cuban Institute of Gastroenterology, 10400 Havana City, Cuba
5National Institute of Hygiene, Epidemiology and Microbiology, 10300 Havana City, Cuba
6Institute of Infectology “Emilio Ribas”, 04610-002 São Paulo, SP, Brazil
7National Centre Coordinator of Clinical Trials, 11600 Havana City, Cuba

Received 15 July 2011; Accepted 8 September 2011

Academic Editor: D. S. Lindsay

Copyright © 2011 Pedro Almirall et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


To compare the efficacy and safety of mebendazole and secnidazole in the treatment of giardiasis in adult patients, a single-centre, parallel group, open-label, randomized non-inferiority trial was carried out. One-hundred and 26 participants who had symptomatic Giardia mono-infection took part in the study. Direct wet mount and/or Ritchie concentration techniques and physical examinations were conducted at the time of enrolment and at the follow-up visit. The primary outcome measure was parasitological cure, performed at 3, 5, 10 days post-treatment. Negative faecal specimens for Giardia were ensured by the same parasitological techniques. At follow up (day 10) the parasitological cure rate for the per protocol populations was 88.7% (55/62) for MBZ and 91.8% (56/61) for SNZ. For the intention to treat populations the cure rate at the end of treatment was 85.9% (55/64) for MBZ and 90.3% (56/62) for SNZ. Both analyzes showed there was not significant statistical difference between MBZ and SNZ treatment efficacy. Both drugs were well tolerated, only mild, transient and self-limited side effects were reported and did not require discontinuation of treatment. A 3-day course of mebendazole seems to be as efficacious and safe for treatment of giardiasis as a single dose of secnidazole in adults.